FY2024 EPS Estimates for Medpace Holdings, Inc. (NASDAQ:MEDP) Lifted by Analyst

Medpace Holdings, Inc. (NASDAQ:MEDP) – Analysts at William Blair lifted their FY2024 earnings per share estimates for Medpace in a report released on Tuesday, April 23rd. William Blair analyst M. Smock now anticipates that the company will post earnings per share of $11.07 for the year, up from their prior estimate of $10.55. The consensus estimate for Medpace’s current full-year earnings is $11.23 per share. William Blair also issued estimates for Medpace’s Q1 2025 earnings at $3.33 EPS and FY2025 earnings at $12.87 EPS.

A number of other research analysts also recently commented on MEDP. Robert W. Baird boosted their price target on Medpace from $446.00 to $454.00 and gave the company an “outperform” rating in a research note on Wednesday. Deutsche Bank Aktiengesellschaft began coverage on Medpace in a research note on Monday, March 18th. They set a “hold” rating and a $395.00 target price for the company. StockNews.com raised Medpace from a “hold” rating to a “buy” rating in a research note on Tuesday. UBS Group raised Medpace from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $282.00 to $452.00 in a research note on Thursday, February 15th. Finally, Jefferies Financial Group raised Medpace from a “hold” rating to a “buy” rating and boosted their target price for the stock from $340.00 to $450.00 in a research note on Tuesday. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, Medpace currently has a consensus rating of “Moderate Buy” and a consensus target price of $443.00.

Medpace Stock Up 1.6 %

MEDP stock opened at $395.93 on Thursday. The company has a market cap of $12.27 billion, a PE ratio of 40.36, a price-to-earnings-growth ratio of 1.98 and a beta of 1.38. The business has a 50-day simple moving average of $397.83 and a 200 day simple moving average of $325.15. Medpace has a 52 week low of $189.30 and a 52 week high of $421.00.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Monday, April 22nd. The company reported $3.20 EPS for the quarter, beating analysts’ consensus estimates of $2.45 by $0.75. The business had revenue of $511.00 million during the quarter, compared to the consensus estimate of $512.39 million. Medpace had a return on equity of 59.74% and a net margin of 15.92%. Medpace’s revenue for the quarter was up 17.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.27 earnings per share.

Institutional Trading of Medpace

Institutional investors have recently added to or reduced their stakes in the stock. Rise Advisors LLC bought a new stake in Medpace in the first quarter valued at approximately $27,000. Mather Group LLC. bought a new stake in Medpace in the first quarter valued at approximately $28,000. Contravisory Investment Management Inc. bought a new stake in Medpace in the fourth quarter valued at approximately $26,000. RiverPark Advisors LLC bought a new stake in Medpace in the fourth quarter valued at approximately $26,000. Finally, Arcadia Investment Management Corp MI boosted its holdings in Medpace by 40.3% in the first quarter. Arcadia Investment Management Corp MI now owns 101 shares of the company’s stock valued at $41,000 after acquiring an additional 29 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors.

Insider Transactions at Medpace

In other news, VP Susan E. Burwig sold 102 shares of the business’s stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $403.00, for a total transaction of $41,106.00. Following the sale, the vice president now directly owns 15,181 shares in the company, valued at $6,117,943. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, VP Susan E. Burwig sold 102 shares of the business’s stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $403.00, for a total transaction of $41,106.00. Following the sale, the vice president now directly owns 15,181 shares in the company, valued at $6,117,943. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Ashley M. Keating sold 250 shares of the business’s stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $409.87, for a total value of $102,467.50. Following the sale, the director now owns 250 shares in the company, valued at $102,467.50. The disclosure for this sale can be found here. Over the last three months, insiders have sold 189,340 shares of company stock worth $76,651,647. Insiders own 20.30% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.